{
    "clinical_study": {
        "@rank": "51908", 
        "arm_group": [
            {
                "arm_group_label": "CNV2197944", 
                "arm_group_type": "Experimental", 
                "description": "CNV2197944 75mg tid 21 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tid 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain\n      experienced in post-herpetic neuralgia (PHN) as measured by changes in PI-NRS after three\n      weeks of treatment compared to the baseline period."
        }, 
        "brief_title": "Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Post-herpetic Neuralgia", 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Neuralgia, Postherpetic"
            ]
        }, 
        "detailed_description": {
            "textblock": "A 3 week randomised crossover study to investigate the effect of repeat oral dosing of\n      CNV2197944 75 mg tid versus placebo for on the pain experienced in post-herpetic neuralgia\n      (PHN. Each 3 week treatment period is seperated by a 2 week washout period. The primary\n      outcome measure is the change from baseline in the PI-NRS after three weeks of treatment.\n      Secondary outcome measures include pain responder rates, clinical and patient global\n      impressions of pain, and the Neuropathic Pain Symptom Inventory."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male or female between 18 and 85 years of age inclusive, at the time of signing the\n        informed consent.\n\n        Patients with post-herpetic neuralgia (PHN) with pain at screening present for more than 3\n        months after healing of the herpes zoster skin rash. The maximum duration of PHN will be\n        no longer than 5 years.\n\n        Exclusion Criteria:\n\n        Patients having other severe pain, which may impair the self-assessment of the pain due to\n        PHN.\n\n        Patients who have received nerve blocks for neuropathic pain within 4 weeks prior to the\n        start of the single-blind placebo run-in Certain medications used to relieve the pain of\n        PHN, specifically gabapentinoids (gabapentin and pregabalin), carbamazepine and topical\n        agents (eg capsaicin, lidocaine) Patients with a documented failure to respond to a\n        maximally tolerated dose regimen of gabapentin or pregabalin.\n\n        Patients taking more than one medication to treat the PHN pain"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848730", 
            "org_study_id": "CNV2197944/201"
        }, 
        "intervention": [
            {
                "arm_group_label": "CNV2197944", 
                "intervention_name": "CNV2197944", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cape Town", 
                    "country": "South Africa"
                }, 
                "name": "Christiaan Barnard Memorial Hospital"
            }
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia", 
        "overall_official": {
            "affiliation": "Christiaan Barnard Memorial Hospital, Cape Town, South Africa", 
            "last_name": "Milton Raff, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "South Africa: Medicines Control Council", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Georgia: Ministry of Health", 
                "Ukraine: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pain Intensity Numerical Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848730"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pain responder rates", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Neuropathic Pain Symptom Inventory", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }
        ], 
        "source": "Convergence Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Convergence Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}